Status:
TERMINATED
NanoSpectrometer Biomarker Discovery and Confirmation Study
Lead Sponsor:
Johns Hopkins University
Collaborating Sponsors:
Nanobeak Inc.
Conditions:
Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
This study will evaluate exhaled volatile organic compounds (VOC's) in the breath of participants with stage 1 lung cancer, their house-mates, and matched controls. The goal of the study is to identif...
Detailed Description
Lung cancer is by far the leading cause of cancer death in the United States. More people die annually of lung cancer than of colon, breast, and prostate cancers combined. Worldwide it is already the ...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Adults age 18 and over with diagnosed Stage 1 Lung Cancer (cases)
- Adults age 18 and over without Lung cancer (type 1 controls)
- Adults age 18 and over who live in the same environment as the cases (type 2 controls)
- Exclusion Criteria N/A
Exclusion
Key Trial Info
Start Date :
September 5 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 6 2020
Estimated Enrollment :
332 Patients enrolled
Trial Details
Trial ID
NCT03275688
Start Date
September 5 2017
End Date
July 6 2020
Last Update
July 22 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Johns Hopkins Hospital
Baltimore, Maryland, United States, 21287